Mitotane treatment for metastatic Leydig cell tumour

Vasileios Chortis¹,², Nicholas J. Johal¹, Irina Bancos¹, Peter Guest⁴, Michael Cullen³, Emilio Porfiri³, Wiebe Arlt¹,²

¹Centre for Endocrinology, Diabetes and Metabolism (CEDAM), School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, B15 2TT, UK
²Department of Endocrinology, ³Cancer Centre, and ⁴Department of Radiology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham. B15 2TH, UK

Introduction

Testicular Leydig cell tumors (LCTs) are rare stromal tumors often associated with androgen excess. Metastatic malignant LCTs tend to progress rapidly and typically show resistance to radiotherapy and cytotoxic chemotherapy, calling for alternative management options. Here we describe our recent experience with the treatment of two patients with metastatic LCTs and severe androgen excess with the adrenolytic drug Mitotane.

Patients

Patient 1: A 51-year-old patient presented with a 6-month history of restlessness, aggressiveness, facial plethora and increasing hirsutism, 15 years after successful orchidectomy for malignant LCT. Imaging by computed tomography revealed disseminated metastatic deposits. Biochemical work-up revealed severe androgen excess underpinning his clinical symptomatology, with a plasma testosterone of 93nmol/L and a 20-fold rise in urinary excretion of active androgen metabolites (androsterone and etiocholanolone), as well as high urinary cortisol.

Patient 2: A 65-year-old patient presented with disseminated disease three years after orchidectomy for LCT. This was also associated with steroid hormone excess, including exceedingly high testosterone (104 nmol/L) and oestradiol. Both patients were commenced on palliative chemotherapy with mitotane.

Results

In both cases, introduction of mitotane led to prompt control of the underlying hormonal excess, with a precipitous decrease in circulating testosterone and oestradiol levels, diminution of the excretion rate of all urinary androgen metabolites and substantial inhibition of 5a-reductase, as demonstrated by serial urine steroid profiling by gas chromatography/mass spectrometry (Fig. 1, 2). Clinically, this resulted in a rapid alleviation of the debilitating clinical symptomatology of hyperandrogenism. Radiologically, stabilization of the rapidly progressive disease was documented on follow-up imaging for 6 months in case 1, while partial response was noted in case 2.

Discussion and Conclusions

Only 8 cases of patients with metastatic LCT treated with mitotane exist in the literature, and treatment lasted more than 2 months in only half of them. Prolonged treatment was associated with good symptomatic control and biochemical response; temporary disease stabilisation was noted in some of these patients. This is the first case series characterising the biochemical response of androgen producing LCTs using the powerful analytical tool of urinary steroid profiling by gas chromatography/mass spectrometry. We suggest consideration of mitotane as a first-line treatment option in inoperable cases of LCTs associated with significant androgen excess, with the primary aim of good biochemical control and symptomatic palliation.

References: